Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ferretti, Gabriela
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises	Active, not recruiting	3	240	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis	08/24	08/24
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Recruiting	3	350	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28
Bezerra, Tamires
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Recruiting	3	350	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28